These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 29248564

  • 1. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC, Li N, Wang Q, Word TA, Sibrian-Vazquez M, Strongin RM, Wehrens XHT, Abramson JJ.
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [Abstract] [Full Text] [Related]

  • 2. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO, Blackwell DJ, Egly CL, Smith AN, Batiste SM, Johnston JN, Laver DR, Knollmann BC.
    Circ Res; 2021 Feb 05; 128(3):321-331. PubMed ID: 33297863
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR.
    Circ Res; 2012 Aug 31; 111(6):708-17. PubMed ID: 22828895
    [Abstract] [Full Text] [Related]

  • 6. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J, Makiyama T, Yamamoto Y, Kobayashi T, Aoki H, Maurissen TL, Wuriyanghai Y, Kashiwa A, Imamura T, Aizawa T, Huang H, Kohjitani H, Nishikawa M, Chonabayashi K, Fukuyama M, Manabe H, Nakau K, Wada T, Kato K, Toyoda F, Yoshida Y, Makita N, Woltjen K, Ohno S, Kurebayashi N, Murayama T, Sakurai T, Horie M, Kimura T.
    Circ Arrhythm Electrophysiol; 2023 Mar 31; 16(3):e011387. PubMed ID: 36866681
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N, Wang Q, Sibrian-Vazquez M, Klipp RC, Reynolds JO, Word TA, Scott L, Salama G, Strongin RM, Abramson JJ, Wehrens XHT.
    Int J Cardiol; 2017 Jan 15; 227():668-673. PubMed ID: 27838126
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B, Walton SD, Ho HT, Belevych AE, Tikunova SB, Bonilla I, Shettigar V, Knollmann BC, Priori SG, Volpe P, Radwański PB, Davis JP, Györke S.
    J Am Heart Assoc; 2018 May 02; 7(10):. PubMed ID: 29720499
    [Abstract] [Full Text] [Related]

  • 12. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R, Wakimoto H, Arad M, Planer D, Konno T, Wang L, Seidman JG, Seidman CE, Berul CI.
    J Cardiovasc Electrophysiol; 2011 Mar 02; 22(3):316-24. PubMed ID: 20807279
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC.
    Circ Arrhythm Electrophysiol; 2011 Apr 02; 4(2):128-35. PubMed ID: 21270101
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG.
    J Mol Cell Cardiol; 2011 Jan 02; 50(1):214-22. PubMed ID: 20937285
    [Abstract] [Full Text] [Related]

  • 18. Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia.
    Nakamura Y, Yamamoto T, Kobayashi S, Tamitani M, Hamada Y, Fukui G, Xu X, Nishimura S, Kato T, Uchinoumi H, Oda T, Okuda S, Yano M.
    JCI Insight; 2019 Jun 06; 4(11):. PubMed ID: 31167968
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.